Wearable sensor collects glucose from cells between hair follicles

Scientists from the University of Bath in the U.K. have developed a non-invasive, adhesive patch capable of accurately measuring glucose levels through the skin without a blood test, according to a study published April 9 in Nature Nanotechnology.

Diabetic patients face a routine of finger pricks to measure blood glucose levels, but researchers have developed this low-cost wearable sensor to measure glucose levels. In the study, researchers explained the development of the wearable and its accuracy in tracking glucose levels.

"A non-invasive—that is, needle-less—method to monitor blood sugar has proven a difficult goal to attain,” said Richard Guy. “The closest that has been achieved has required either at least a single-point calibration with a classic 'finger-stick,’ or the implantation of a pre-calibrated sensor via a single needle insertion. The monitor developed at Bath promises a truly calibration-free approach, an essential contribution in the fight to combat the ever-increasing global incidence of diabetes."

The wearable patch sits on the skin and collects glucose in reservoirs from the fluid from the cells between hair follicles. The fluid is then examined on the patch’s sensor using a small electric current. Results are compiled within 15 minutes and sent to a mobile phone or smartwatch for easy viewing.

“The specific architecture of our array permits calibration-free operation, and it has the further benefit of allowing realization with a variety of materials in combination,” said Adelina Ilie, from the Department of Physics. “We utilized graphene as one of the components as it brings important advantages: specifically, it is strong, conductive, flexible, and potentially low-cost and environmentally friendly. In addition, our design can be implemented using high-throughput fabrication techniques like screen printing, which we hope will ultimately support a disposable, widely affordable device."

In the study, researchers evaluated the accuracy of the device on both pig skin and healthy human participants. The wearable showed it could accurately track glucose levels in ranges seen in diabetic human patients on the pig skin while also showing its capability to track blood glucose long-term in healthy human participants.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.